Publications by authors named "Maria D Fenor de la Maza"
Article Synopsis
- * Although clinical trials show PARPi can be effective, there is still a need for better biomarkers to predict which patients will benefit most.
- * The review highlights how PARPi works as both a standalone treatment and in combination with other drugs, while also discussing necessary future developments for treating advanced prostate cancer.
Article Synopsis
- The treatment landscape for metastatic urothelial carcinoma is evolving, with the combination of pembrolizumab and enfortumab vedotin emerging as a potentially better option than traditional platinum-based chemotherapies.
- New challenges arise regarding the best second-line treatments and the importance of molecular profiling of tumors in therapy selection.
- Recent trials have shown that combining nivolumab with platinum-based chemotherapy may be more effective than chemotherapy alone, highlighting the need for further translational research to understand these differing results.
Inflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and therapeutic modalities. Whether myeloid inflammation drives progression of prostate cancer in humans remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- B7-H3 is a key protein found on the surface of prostate cancer cells, particularly in castration-resistant prostate cancer (CRPC), and its role in cancer therapy is being studied to help target treatments more effectively.
- Researchers analyzed samples from 98 prostate cancer patients, comparing hormone-sensitive and castration-resistant biopsies to evaluate B7-H3 expression and link it to genomic data.
- The study found that B7-H3 is highly expressed in the majority of CRPC cases and remained stable during the transition from hormone-sensitive to castration-resistant stages, indicating its potential as a target for antibody-drug conjugate therapies.
Background: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited.
Objective: To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC and to determine their association with overall survival (OS).
Article Synopsis
- The study investigates the role of ATM (Ataxia Telangiectasia Mutated) gene alterations in metastatic prostate cancer, revealing that about 11% of patients show ATM loss in biopsies, which is often linked to genomic instability.
- Researchers utilized advanced techniques like immunohistochemistry and next-generation sequencing to analyze cancer biopsies and created modified cell models to test drug responses, finding that ATM-deficient cancers respond variably to PARP inhibitors but exhibit better results with combined ATR and PARP inhibition.
- Despite ATM loss not correlating with worse clinical outcomes, it signifies a distinct and potentially targetable subtype of aggressive prostate cancer, emphasizing the need for tailored treatment strategies.
Purpose: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic, and tumor-infiltrating lymphocyte (TIL) data.
Experimental Design: Patients with mCRPC consented to the molecular analyses of diagnostic and mCRPC biopsies.